• Super-Enhancer-Driven KLF6 Regulates Adipogenesis in hADSCs

  2026-07-21

  Nguyen et al. elucidate how super-enhancer (SE)-mediated upregulation of KLF6 is a key determinant in the adipogenic differentiation of human adipose-derived stem cells (hADSCs). Their integrative approach highlights the role of BET bromodomain inhibition in modulating adipogenesis through KLF6 transcriptional control, with implications for both metabolic research and methodological strategies targeting enhancer function.

• Optimizing PKC Pathway Assays with Go 6983 (pan-PKC inhibito

  2026-07-21

  This article addresses core laboratory challenges in PKC signaling pathway research, cell viability assays, and translational neurobehavioral models, focusing on the practical applications and workflow reliability of Go 6983 (pan-PKC inhibitor, SKU A8343). Drawing from validated evidence and real-world lab scenarios, it demonstrates how APExBIO’s Go 6983 empowers researchers to achieve reproducible, high-sensitivity results in cancer and neurobiology studies.

• Nicotinamide Riboside Chloride (NIAGEN) in Retinal and Neuro

  2026-07-20

  Explore how Nicotinamide Riboside Chloride (NIAGEN) advances retinal and neurodegenerative disease research through NAD+ metabolism and sirtuin modulation. Discover new assay strategies and practical insights distinct from prior coverage.

• Sunitinib: Multi-Targeted RTK Inhibitor in Renal Cell Carcin

  2026-07-20

  Sunitinib, a multi-targeted receptor tyrosine kinase inhibitor, is a cornerstone of renal cell carcinoma investigations. It exhibits potent nanomolar inhibitory activity against VEGFR and PDGFR, inducing apoptosis and cell cycle arrest in diverse tumor models. Recent evidence highlights enhanced sensitivity when combined with agents such as chrysin.

• Indomethacin: Practical Guide for Inflammation and Lipid Res

  2026-07-19

  Indomethacin (SKU A8449) is a selective nonsteroidal anti-inflammatory drug (NSAID) used for dissecting cyclooxygenase and PPAR-mediated mechanisms in inflammation research, lipid metabolism study, and membrane signaling modulation. It is not suitable for applications requiring aqueous solubility or long-term solution storage due to its chemical properties.

• Berberine Hydrochloride: Protocols and Troubleshooting for M

  2026-07-18

  Berberine Hydrochloride unlocks advanced metabolic and cardiovascular workflows by activating AMPK, modulating lipid metabolism, and promoting apoptosis in cancer models. This article delivers practical protocols, comparative insights, and troubleshooting strategies to maximize translational research impact.

• Dasatinib (BMS-354825): Beyond Kinase Inhibition in Cancer M

  2026-07-17

  Explore the multifaceted applications of Dasatinib (BMS-354825) in cancer research, delving into its role in modulating tumor microenvironments and EMT. This article provides new insights into practical assay design and therapeutic targeting, setting it apart from standard kinase-focused guides.

• Gingerenone A Reverses Sunitinib Resistance in Renal Cell Ca

  2026-07-17

  This study demonstrates that gingerenone A (GA), a natural phenolic compound, restores sunitinib sensitivity in renal cell carcinoma (RCC) by inhibiting LDHA-mediated glycolysis and disrupting the HIF-1α/VEGFA/VEGFR2 pathway. The findings highlight a metabolic-targeted strategy to overcome resistance to multi-targeted tyrosine kinase inhibitors in RCC research.

• Quercetin Inhibits Ferroptosis to Protect Liver in Wilson’s

  2026-07-16

  A recent study reveals that quercetin directly inhibits the ACSL4/LPCAT3/ALOX15 pathway, blocking ferroptosis and alleviating liver injury in Wilson’s disease models. These findings clarify the mechanistic basis for quercetin’s impact on hepatic protection and provide a platform for targeted ferroptosis research in metal overload disorders.

• L-Phenylephrine: A Selective Adrenergic α1A Receptor Agonist

  2026-07-16

  L-Phenylephrine is a selective adrenergic α1A receptor agonist with a Ki of 1.4 μM, exhibiting potent vasoconstrictive effects and precise modulation of cardiac and neural cell signaling. Its robust selectivity profile, in vitro and in vivo efficacy, and clear limitations in receptor subtype specificity make it a valuable tool in cardiovascular and neurobiological research.

• CD28-ARS2-PKM Axis Drives CD8+ T Cell Metabolic Flexibility

  2026-07-15

  This study uncovers how CD28-driven upregulation of ARS2 orchestrates alternative splicing in CD8+ T cells, promoting PKM2 expression and enhancing metabolic adaptability vital for antitumor immunity. The findings reveal a novel, PI3K-independent pathway for controlling T cell glycolysis that could inform new immunometabolic interventions.

• ORM2-ZG16 Interaction Alleviates Pancreatic Fibrosis via Aut

  2026-07-15

  The reference study uncovers ORM2 as a pivotal regulator of pancreatic fibrosis in chronic pancreatitis by inhibiting autophagy-driven activation of pancreatic stellate cells through its interaction with ZG16. These findings highlight a novel mechanistic axis and offer new therapeutic insights for targeting fibrotic progression in the pancreas.

• Macrophage EV-Encapsulated miR-660 Drives Breast Cancer Meta

  2026-07-14

  This study reveals how tumor-associated macrophage-derived extracellular vesicles (EVs) deliver microRNA-660 to breast cancer cells, thereby promoting metastasis through suppression of KLHL21 and activation of the NF-κB signaling pathway. The findings highlight new molecular targets for intervention in metastatic breast cancer and elucidate mechanisms of tumor–immune cell communication.

• Puromycin Aminonucleoside: Precision Podocyte Injury Modelin

  2026-07-14

  Puromycin aminonucleoside empowers nephrology researchers to induce reproducible podocyte injury and model focal segmental glomerulosclerosis (FSGS) in vivo and in vitro. Explore advanced workflows, real troubleshooting, and actionable protocol tips that maximize the translational value of this aminonucleoside moiety of puromycin.

• Sunitinib as a Multi-Targeted RTK Inhibitor: Protocols and P

  2026-07-13

  Sunitinib offers precision inhibition of key RTKs, enabling advanced modeling of tumor angiogenesis, apoptosis, and cell cycle arrest in cancer research. This article translates mechanistic advances and experimental workflow optimizations into actionable guidance for maximizing Sunitinib’s impact, with an emphasis on ATRX-deficient and renal cell carcinoma models.

16439 records 1/1096 page Next 12345 下5页 Last page